In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer

Archives of Gynecology and Obstetrics

Volumn 289, Issue 1, 2014, Pages 155-162

  Wang, Hua Li ^a   Xu, Hui ^a   Lu, Wei Hua ^b   Zhu, Lin ^a   Yu, Yun Hai ^a   Hong, Fan Zhen ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b First People's Hospital of Ningyang County   (China)

Author keywords

CpG ODN2006; Dendritic cells; HPV16E7 polypeptide; Immunotherapy

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 12; PROTEIN E7; CANCER VACCINE; CPG ODN 2006; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR VOLUME; UTERINE CERVIX CARCINOMA; ADENOCARCINOMA; ANIMAL; DENDRITIC CELL; DISEASE MODEL; HELA CELL LINE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; SCID MOUSE; UTERINE CERVICAL NEOPLASMS;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-12; MICE; MICE, SCID; OLIGODEOXYRIBONUCLEOTIDES; UTERINE CERVICAL NEOPLASMS;

EID: 84891881802     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-2938-1     Document Type: Article

References (29)

1. Pagliusi S, Organization WH (2006) Human papillomavirus infection and cervical cancer. World Health Organization Web site http://www.who.int/vaccine- research/diseases/hpv/en/(Slide14)
2. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE et al (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11:1048-1056
3. Moody CA, Laimins LA (2010) Human papillomavirus oncoproteins: pathways to transformation. Nature Rev Cancer 10:550-560
4. Stoler MH (2000) Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol 19:16-28 (Pubitemid 30010639)
5. Nonn M, Schinz M, Zumbach K, Pawlita M, Schneider A et al (2003) Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7. J Cancer Res Clin Oncol 129:511-520 (Pubitemid 37211192)
6. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A et al (2008) Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 82:1968-1979 (Pubitemid 351206942)
7. Rock KL, York IA, Saric T, Goldberg AL (2002) Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 80:1-70 (Pubitemid 34625620)
8. Zhou L, Zhu T, Ye X, Yang L, Wang B et al (2009) Long-term protection against human papillomavirus E7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated E7 of human papillomavirus 16/18 and heat shock protein 70. Hum Gene Ther 21:109-119
9. van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ et al (1999) Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 35:946-952 (Pubitemid 29277130)
10. Vierboom MP, Feltkamp MC, Neisig A, Drijfhout JW, ter Schegget J et al (1998) Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J Immunother 21:399-408 (Pubitemid 28493710)
11. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT et al (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21-26 (Pubitemid 26010379)
12. Pvd Bruggen, Eynde BJ (2006) Processing and presentation of tumor antigens and vaccination strategies. Cur opin immunol 18:98-104 (Pubitemid 43049655)
13. + dendritic cells. J Immunol 166:5000-5007 (Pubitemid 32280712)
14. Hacker G, Redecke V, Hacker H (2002) Activation of the immune system by bacterial CpG-DNA. Immunology 105:245-251 (Pubitemid 34304400)
15. Mutwiri G, Pontarollo R, Babiuk S, Griebel P, van Drunen Littel-van den Hurk S et al (2003) Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet Immunol Immunopathol 91: 89-103 (Pubitemid 36113256)
16. Kim TG, Kim CH, Won EH, Bae SM, Ahn WS et al (2004) CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology 112:117-125 (Pubitemid 38609829)
17. Krieg AM (2001) From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug Dev 11:181-188 (Pubitemid 32613529)
18. O'Neill DW, Adams S, Bhardwaj N (2004) Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104:2235-2246 (Pubitemid 39331818)
19. Edmondson JM, Armstrong LS, Martinez AO (1988) A rapid and simple MTT-based spectrophotometric assay for determining drug sensitivity in monolayer cultures. J Tissue Culture Methods 11:15-17
20. Alli RS, Khar A (2004) Interleukin-12 secreted by mature dendritic cells mediates activation of NK cell function. FEBS Lett 559:71-76 (Pubitemid 38186706)
21. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J et al (2010) Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Develop Immunol 2010. 10.1155/2010/832454
22. Ahn W-S, Bae S-M, Kim T-Y, Kim T-G, Lee J-M et al (2003) A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Human Gene Ther 14:1389-1399 (Pubitemid 37268218)
23. Hemmi H, Kaisho T, Takeda K, Akira S (2003) The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 170:3059-3064 (Pubitemid 36304671)
24. Kline JN, Krieg AM (2010) Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapylate. Prog Respir Res 39:95-99
25. Ma C, Muranyi M, Chu CH, Zhang J, Chu W-M (2013) Involvement of DNA-PKcs in the IL-6 and IL-12 response to CpG-ODN is mediated by its interaction with TRAF6 in dendritic cells. PLoS ONE 8:e58072
26. Kreis N, Sanhaji M, Krämer A, Sommer K, Rödel F et al (2010) Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells. Oncogene 29:5591-5603
27. Woo SJ, Kim CH, Park MY, Kim HS, Sohn HJ et al (2008) Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG- oligodeoxynucleotide induces potent antitumor immunity. Cancer Sci 99:1034-1039 (Pubitemid 351997609)
28. + T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14:178-187 (Pubitemid 351377994)
29. + T Cells in protection. Cancer Res 62:7234-7240 (Pubitemid 36025244)